CGEN vs. SGMO

In the year-to-date period, CGEN achieves a -22.73% return, which is significantly lower than SGMO's 354.63% return. Both investments have delivered pretty close results over the past 10 years, with CGEN having a -16.03% annualized return and SGMO not far behind at -16.08%.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Compugen Ltd. (CGEN) and Sangamo Therapeutics, Inc. (SGMO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current CGEN Sharpe Ratio is -0.24, which is lower than the SGMO Sharpe Ratio of 3.72. The chart below compares the historical Sharpe Ratios of CGEN and SGMO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither CGEN nor SGMO has paid dividends to shareholders.

The maximum CGEN drawdown since its inception was -97.90%, roughly equal to the maximum SGMO drawdown of -99.40%. Use the drawdown chart below to compare losses from any high point for CGEN and SGMO. For additional features, visit the drawdowns tool.

The current volatility for Compugen Ltd. (CGEN) is 14.61%, while Sangamo Therapeutics, Inc. (SGMO) has a volatility of 39.68%. This indicates that CGEN experiences smaller price fluctuations and is considered to be less risky than SGMO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Compugen Ltd. and Sangamo Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.